Question 1

What are the potential benefits of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer clinical trial (NCT00047801). Contact the study team or your healthcare provider for specific answers.

Question 2

How does TLK286 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer clinical trial (NCT00047801). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from TLK286 and docetaxel?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer clinical trial (NCT00047801). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatments and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer clinical trial (NCT00047801). Contact the study team or your healthcare provider for specific answers.

Question 5

What will happen if my cancer progresses during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer clinical trial (NCT00047801). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer clinical trial (NCT00047801). Contact the study team or your healthcare provider for specific answers.

What this study is about